title: Mycophenolate mofetil (MMF) in the treatment of chronic renal rejection.
abstract: BACKGROUND
  Experimental studies suggest the efficacy of MMF in the treatment of chronic renal rejection in rats. Studies on the efficacy of MMF in chronic renal rejection in man are scarce and controversial.
  
  
  OBJECTIVE
  The aim of this study was to verify in a prospective non-randomized study the efficacy of MMF given at the dose of 2 g/day in substitution of azathioprine (AZA) in the chronic rejection of cadaveric kidney transplantation.
  
  
  METHODS
  Twelve patients with histologically proven chronic renal rejection were enrolled. The patients were 5 males and 7 females. Mean age 38.3 +/- 13.8 years, with a mean duration of transplant of 39 +/- 19 months. Mean serum creatinine values at -6, -3, 0, +3, +6, +12 months were respectively 1.72 +/- 0.33, 1.84 +/- 0.36, 2.15 +/- 0.50, 1.88 +/- 0.54, 1.81 +/- 0.71, 1.73 +/- 0.58 mg/dl. Mean creatinine clearance values were 58.85 +/- 10.06,48.8 +/- 13.3,45.8 +/- 10.2, 54.7 +/- 13.3, 51 +/- 12.7, 57.7 +/- 18.5 ml/min. Mean deltaGFR before MMF was -2.15 ml/month.
  
  
  RESULTS
  After MMF introduction, the overall GFR decrease attenuated. In particular in seven patients after MMF administration, we obtained a significant reduction of mean serum creatinine value (1.84 +/- 0.55 vs. 1.38 +/- 0.41mg/dl; p = 0.004). In three patients, we obtained a stabilization in GFR. Two patients were slowly progressing even after MMF introduction. After a switch to MMF in almost all patients, we obtained an improvement of renal function. In three patients, we obtained a stabilization of renal function without regression. In particular, seven patients showed a remarkable improvement of renal function.
  
  
  CONCLUSIONS
  In conclusion our data even if concerning a small number of patients, confirm the efficacy of MMF in the treatment of renal allograft chronic dysfunction.
authors.affiliation: Renal Unit, Careggi University Hospital, Florence, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Di Maria
authors.forename: E
authors.initials: E
authors.lastname: Bertoni
authors.forename: A
authors.initials: A
authors.lastname: Rosati
authors.forename: M
authors.initials: M
authors.lastname: Zanazzi
authors.forename: R
authors.initials: R
authors.lastname: Piperno
authors.forename: L
authors.initials: L
authors.lastname: Moscarelli
authors.forename: G
authors.initials: G
authors.lastname: Toti
authors.forename: F M
authors.initials: FM
authors.lastname: Casini
authors.forename: S
authors.initials: S
authors.lastname: Bandini
authors.forename: M
authors.initials: M
authors.lastname: Salvadori
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid